HER2+ Breast Cancer
>
The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
Latest News
TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
%20(2)%201-Recovered-Recovered-Recovered%20copy.jpg?fit=crop&auto=format)
